How to Get Tirzepatide: Brand vs Compounded Routes and Prices
To get tirzepatide you need a prescription. Then use insurance, or self-pay from $299 a month (LillyDirect: LillyDirect vial or KwikPen 2.5 mg).
- Prescription
- Required
- Lowest self-pay
- $299 a month
- Telehealth from, all in
- $373 a month
- Shortage
- Resolved
Zepbound in brief
Half-life: 5 to 6 days. At 5.5 d, half is gone, and by the fifth half-life, 27.5 d, about 3% is left.
In SURMOUNT-1 over 72 weeks, weight loss reached 20.9% of body weight, compared with 3.1% on placebo.
In US dollars, the monthly price points cover list price and self-pay offers, and each one is read from the maker's price page.
Sources: FDA label (DailyMed), Eli Lilly 1 2, cnbc.com.
Every legit way to get tirzepatide, ranked
| Route | Who it is for | What you pay |
|---|---|---|
| Mounjaro: Get it through your doctor using insurance and the savings card | Commercial insurance that covers it | For up to a 3-month fill, you may pay as little as $25 |
| Zepbound: Get it through your doctor using insurance and the savings card | Commercial insurance that covers it | For up to a 3-month fill, you may pay as little as $25 |
| Zepbound: LillyDirect: LillyDirect vial or KwikPen 2.5 mg | Anyone with a prescription, no insurance needed | $299 a month |
| Zepbound: TrumpRx listing (vial, starting) | Self-pay only | $299 a month |
| Zepbound: Walmart Pharmacy: LillyDirect self-pay (lowest dose) | Cash at the pharmacy counter | $299 a month |
| Telehealth: WeightWatchers Med+, Zepbound (self-pay) | Online visit, medicine shipped | $373 a month all in |
| Compounded copy: Mochi Health | Not FDA approved; ranked last for that reason | $90 a month |
Prices checked November 2026. Each price links to the page where it comes from.
Sources: pricinginfo.lilly.com, mounjaro.lilly.com, GoodRx, zepbound.lilly.com.
Who qualifies for it
Any GLP-1 sold in the US requires a prescription. A prescriber writes it for a use the label approves:
- Mounjaro: This drug, used with diet and exercise, brings blood sugar down in adults and children aged 10 and older with type 2 diabetes.
- Mounjaro: For adults with type 2 diabetes who face a high risk, the drug lowers the risk of heart attack, stroke or heart-related death.
- Zepbound: With diet and physical activity, this drug supports weight loss and helps keep weight off long term for adults with obesity, and for adults who are overweight and also have a weight-related condition.
- Zepbound: It treats moderate to severe obstructive sleep apnea in adults with obesity.
Source: FDA label (DailyMed).
Telehealth options compared
| Program | Medicine option | Medicine price | Membership | All in |
|---|---|---|---|---|
| Zepbound (self-pay) | $299 a month | $74 a month | $373 a month | |
| Zepbound KwikPen, starting dose | $299 a month | $149 a month | $448 a month | |
| Zepbound | $1,899 a month | $149 a month after first month | $2,048 a month | |
| Mounjaro | $1,899 a month | $149 a month after first month | $2,048 a month | |
| Compounded tirzepatide (not FDA approved) | $90 a month | $79 a month after free first month | $169 a month | |
| Compounded GLP-1 plan (not FDA approved) | $99 a month | $169 a month cash | $268 a month | |
| GLP-1Rx Plus Program (compounded GLP-1 with GIP, not FDA approved) | once the first 4 weeks have passed, $299 a month, billed quarterly | Not listed | Included |
Each program's own pricing page lists the prices. No money comes to us from any of them.
Sources: weightwatchers.com, ro.co, hims.com, joinmochi.com.
Shortage status update
Tirzepatide: Shortage resolved. The FDA confirmed this on December 19, 2024.
- First date on the FDA shortage list: December 15, 2022
- Shortage resolved: December 19, 2024
- State pharmacies had to stop making compounding copies: February 18, 2025
- Outsourcing facilities had to stop on March 19, 2025
Source: FDA.
Scam signals
- No prescription needed: A seller that skips the prescription cannot operate as a licensed US pharmacy.
- Paying on your own for this brand starts at $299 a month, far below what the manufacturer charges.
- Marketing a compounded drug as the brand: no compounded drug has FDA approval, so none of them is Ozempic, Wegovy, Mounjaro, or the brand Zepbound.
- Claims that it is the same as the brand: The FDA issued 30 warning letters about misleading claims to telehealth companies.
- Harm reports: the FDA has counted more than 730 adverse event reports tied to compounded tirzepatide.
- Monthly prices that leave out the drug: the FTC acted against one program over this; see the NextMed program review.
Sources: pricinginfo.lilly.com, mounjaro.lilly.com, GoodRx, zepbound.lilly.com.
Find it in your state
- Hims & Hers: Not in all 50 states
- Noom Med: Not in all 50 states
- NovoCare Pharmacy: (delivery network) covers all 50 states, DC, Puerto Rico
More than anything else, Medicaid rules change which route you take. 10 state Medicaid programs cover GLP-1s used for weight loss today. Pick your state to check its drug list and prior authorization rules:
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming